Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0194-0499, cagrilintide, and semaglutide in alcohol-related liver disease
jRCT2011240020Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides, Hormonal Peptides → Native Peptides → Peptides
01
Overview
Randomised, double-blind trial of nn9500, cagrilintide and semaglutide in alcoholic liver disease (ALD) (7 arms), sponsored by Novo Nordisk. Primary endpoint: Change in Enhanced Liver Fibrosis score from baseline to week 28. Started Jun 2024; status: completed.
02
Drugs
03
Conditions
alcoholic liver disease (ALD)
Beyond the preview
Go deeper on jRCT2011240020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240020.